- Home
- MYGN vs CGNT Comparison
MYGN vs CGNT Comparison
Compare MYGN & CGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CGNT
- Stock Information
- Founded
- MYGN 1991
- CGNT 2020
- Country
- MYGN United States
- CGNT Israel
- Employees
- MYGN N/A
- CGNT N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CGNT Computer Software: Prepackaged Software
- Sector
- MYGN Health Care
- CGNT Technology
- Exchange
- MYGN Nasdaq
- CGNT Nasdaq
- Market Cap
- MYGN 744.7M
- CGNT 680.1M
- IPO Year
- MYGN 1995
- CGNT N/A
- Fundamental
- Price
- MYGN $7.29
- CGNT $9.30
- Analyst Decision
- MYGN Hold
- CGNT Hold
- Analyst Count
- MYGN 16
- CGNT 2
- Target Price
- MYGN $20.17
- CGNT $9.00
- AVG Volume (30 Days)
- MYGN 1.2M
- CGNT 609.0K
- Earning Date
- MYGN 05-06-2025
- CGNT 06-17-2025
- Dividend Yield
- MYGN N/A
- CGNT N/A
- EPS Growth
- MYGN N/A
- CGNT N/A
- EPS
- MYGN N/A
- CGNT N/A
- Revenue
- MYGN $837,600,000.00
- CGNT $350,632,000.00
- Revenue This Year
- MYGN $2.99
- CGNT $13.87
- Revenue Next Year
- MYGN $8.36
- CGNT $9.64
- P/E Ratio
- MYGN N/A
- CGNT N/A
- Revenue Growth
- MYGN 11.21
- CGNT 11.88
- 52 Week Low
- MYGN $7.35
- CGNT $6.21
- 52 Week High
- MYGN $29.30
- CGNT $11.12
- Technical
- Relative Strength Index (RSI)
- MYGN 25.95
- CGNT 53.57
- Support Level
- MYGN $7.69
- CGNT $9.10
- Resistance Level
- MYGN $8.27
- CGNT $9.91
- Average True Range (ATR)
- MYGN 0.56
- CGNT 0.53
- MACD
- MYGN 0.02
- CGNT 0.02
- Stochastic Oscillator
- MYGN 1.02
- CGNT 45.95
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.